Skip to main content
. 2013 Jan 31;8(1):e54674. doi: 10.1371/journal.pone.0054674

Table 2. Univariate analyses of DFS and OS according to the expression of CD31 and nucleolin in all patients and subgroups with clinicopathologic variables (Log-rank test).

Surface expression No. of patients (%) DFS (5-year) OS (5-year)
(%) P value (%) P value
Total
CD31loNCLlo 52 (35.7) 64 72
CD31hiNCLlo 44 (30.1) 50 65
CD31hiNCLhi 50 (34.2) 24 0.002 69 0.841
Histology
ADC*
 CD31loNCLlo 25 (29.1) 57 71
 CD31hiNCLlo 31 (36.0) 47 62
 CD31hiNCLhi 30 (34.9) 21 0.061 73 0.837
 SCC‡+ADSCC§
 CD31loNCLlo 27 (45) 70 73
 CD31hiNCLlo 13 (21.7) 56 69
 CD31hiNCLhi 20 (33.3) 27 0.028 64 0.805
Tumor differentiation
Low
 CD31loNCLlo 26 (40.6) 46 64
 CD31hiNCLlo 16 (25) 42 56
 CD31hiNCLhi 22 (34.4) 8 0.038 57 0.782
Median, High
 CD31loNCLlo 26 (31.8) 82 80
 CD31hiNCLlo 28 (34.1) 54 70
 CD31hiNCLhi 28 (34.1) 35 0.01 79 0.873
Tumor size
<5 cm
 CD31loNCLlo 36 (39.1) 73 74
 CD31hiNCLlo 30 (32.6) 56 76
 CD31hiNCLhi 26 (28.3) 24 0.008 85 0.843
≥5 cm
 CD31loNCLlo 16 (29.6) 43 69
 CD31hiNCLlo 14 (25.9) 37 39
 CD31hiNCLhi 24 (44.5) 26 0.392 51 0.795
Overall stage
Stage I
 CD31loNCLlo 26 (40.6) 91 88
 CD31hiNCLlo 17 (26.6) 74 94
 CD31hiNCLhi 21 (32.8) 25 <0.001 90 0.474
Stage II∼III
 CD31loNCLlo 26 (31.7) 37 55
 CD31hiNCLlo 27 (32.9) 35 45
 CD31hiNCLhi 29 (35.4) 24 0.374 54 0.825
Treatment
Surgery alone
 CD31loNCLlo 34 (39.5) 69 73
 CD31hiNCLlo 20 (23.3) 61 67
 CD31hiNCLhi 32 (37.2) 29 0.015 78 0.969
Surgery+other(s)
 CD31loNCLlo 18 (30) 56 71
 CD31hiNCLlo 24 (40) 39 63
 CD31hiNCLhi 18 (30) 14 0.088 56 0.619